Pure Biologics Company Description
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases.
It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules.
The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.
It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis; and provides contract research for pharmaceutical and biotechnology companies.
Pure Biologics S.A. was incorporated in 2010 and is headquartered in Wroclaw, Poland.
Country | Poland |
Founded | 2010 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 51 |
Contact Details
Address: ul. Dunska 11 Wroclaw, 54-427 Poland | |
Phone | 48 795 61 18 11 |
Website | purebiologics.com |
Stock Details
Ticker Symbol | PUR |
Exchange | Warsaw Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | PLN |
ISIN Number | PLPRBLG00010 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Filip Jelen M.B.A., Ph.D. | Co-founder and President of the Management Board |
Romuald Apollo Harwas | Chief Financial Officer and Member of the Management Board |
Dr. Pieter Spee | Chief Scientific Officer and Member of the Management Board |
Przemyslaw Dudek | Head of Information Technology |
Dr. Ewelina Swiderek Ph.D. | Head of Project Management |